IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.

AUSTIN, Texas, Sept. 18, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of  The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Ehud Geller, Executive Chairman and CEO of Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions.

To begin the interview, Geller provided an overview of Regentis’ regenerative medicine platform and its lead product, GelrinC^®, which is being developed to treat cartilage injuries in the knee.

“Our company, Regentis, is focused on developing technologies for regeneration of tissue, hence the name,” Geller said. “In our particular case, we have a platform from which we can develop a variety of applications. Currently, our lead product is called GelrinC^®. Gelrin is the platform and C stands for cartilage, and we are specifically focused on treating cartilage injuries to the knee. We are already approved for marketing in Europe, and we are in the midst of our clinical trial, the pivotal trial which will get us permission from the FDA to start marketing in the U.S.”

Turning to the market opportunity, Geller discussed the prevalence of cartilage injuries among knee-related conditions and the size of the U.S. market Regentis is targeting.

“We believe that there are two layers to that market. The very obvious one: a patient comes to the doctor suffering from pain in his knee, and he would probably have one of three potential pathologies,” Geller said. “The major one, covering more than 50% of the cases, is ours. The total U.S. market annually is 470,000 cases a year, and that is the size of the market currently untreated.”

Looking at Regentis’ priorities for the remainder of 2026, Geller highlighted continued enrollment in the company’s U.S. pivotal study as well as efforts to advance commercialization in Europe.

“We want to finish enrolling the balance of our patients for the U.S. pivotal study, which we’re now running,” Geller said. “We’re in the midst of that study, and our team is right now opening more sites for a clinical study in the U.S. to speed up the enrollment, which we hope to finish by approximately the end of the year. Another thing that we’re doing is working quite actively on commercialization. We have approval in Europe, so we are permitted already to market and sell in Europe. Following our IPO, we started activities toward that. We are in discussion with a number of distribution systems and/or strategic major orthopedic companies in Europe.”

To close the interview, Dr. Geller said, “The message we bring to the market is one of a short, 10-minute procedure with two weeks of recovery, and I must say we've put in front of us durability as a slogan for the company. We need to treat patients in a way that will hold for a long time.”

Join IBN’s Stuart Smith for a conversation with Dr. Ehud Geller, Executive Chairman and CEO of Regentis Biomaterials, as he further explores GelrinC®, the company’s U.S. pivotal study and European commercialization strategy, the market opportunity for cartilage repair, its broader regenerative medicine platform, intellectual property portfolio and key development and commercial milestones.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 20 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.Ai/Timeline

About Regentis Biomaterials

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis' Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis' lead product GelrinC^®, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC^® aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.

For more information, visit the company’s website at www.Regentis.co.il

About IBN

IBN consists of financial brands introduced to the investment public over the course of 20+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.IBN.Ai

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

This content was disseminated on behalf of (NYSE American: RGNT) as part of a paid marketing engagement with IBN.Ai

RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN

Corporate Communications

IBN
Austin, Texas
IBN.Ai
512.354.7000 Office
Editor@IBN.Ai